Basic Stats
| CIK | 1182129 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Auxilium Pharmaceuticals Inc
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| February 16, 2016 |
AUXL / Auxilium Pharmaceuticals Inc / Palo Alto Investors, LLC Passive Investment SC 13G/A 1 Auxilium13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Auxilium Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05334D107 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| March 5, 2015 |
SC TO-I/A 1 d887287dsctoia.htm AMENDMENT NO. 2 TO SCHEDULE TO-I SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) AUXILIUM PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) AUXILIUM PHARMACEUTICALS, INC. (Names of Filing Person (Issuer)) 1.50% Convertible Se |
|
| February 18, 2015 |
AUXL / Auxilium Pharmaceuticals Inc / Palo Alto Investors, LLC - SC 13G/A Passive Investment SC 13G/A 1 Auxilium13Ga2.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Auxilium Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05334D107 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 17, 2015 |
SC 13G 1 auxl21715.htm AQR CAPITAL MANAGEMENT LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Auxilium Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.01 par value (Title of Class of Securities) 05334D107 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Statemen |
|
| February 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* AUXILIUM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 05334D107 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2015 |
AUXL / Auxilium Pharmaceuticals Inc / VANGUARD GROUP INC Passive Investment SC 13G/A 1 auxiliumpharmainc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: Auxilium Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 05334D107 Date of Event Which Requires Filing of this Statement: December 31, 2014 Check the appropriate box to designate the rule |
|
| February 9, 2015 |
AUXL / Auxilium Pharmaceuticals Inc 15-12G - - 15-12G 15-12G 1 d867249d1512g.htm 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-50855 AUXILIUM PHARMACEUTICALS, INC. ( |
|
| February 4, 2015 |
EX-99.(a)(1)(B) Exhibit (a)(1)(B) AMENDMENT AND SUPPLEMENT TO FUNDAMENTAL CHANGE PURCHASE RIGHT NOTICE, NOTICE OF RIGHT TO CONVERT AND NOTICE OF ENTRY INTO SUPPLEMENTAL INDENTURE AND OFFER TO PURCHASE TO HOLDERS OF 1.50% CONVERTIBLE SENIOR NOTES DUE 2018 ISSUED BY AUXILIUM PHARMACEUTICALS, INC. CUSIP NUMBER: 05334D AA5 This Amendment and Supplement to the Fundamental Change Purchase Right Notice, |
|
| February 4, 2015 |
AUXL / Auxilium Pharmaceuticals Inc SC TO-I/A - - AMENDMENT NO. 1 TO SCHEDULE TO-I SC TO-I/A 1 d865474dsctoia.htm AMENDMENT NO. 1 TO SCHEDULE TO-I SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) AUXILIUM PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) AUXILIUM PHARMACEUTICALS, INC. (Names of Filing Person (Issuer)) 1.50% Convertible Se |
|
| February 4, 2015 |
AUXL / Auxilium Pharmaceuticals Inc / Flynn James E Passive Investment SC 13G/A 1 e613270sc13ga-auxilium.htm SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3) * Auxilium Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05334D107 (CUSIP Number) |
|
| February 3, 2015 |
AUXL / Auxilium Pharmaceuticals Inc SC TO-I - - SC-TO-I SC-TO-I SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 AUXILIUM PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) AUXILIUM PHARMACEUTICALS, INC. (Names of Filing Person (Issuer)) 1.50% Convertible Senior Notes Due 2018 (Title of Class of Securities) 05334D AA5 (CUSIP Numbe |
|
| February 3, 2015 |
EX-99.(a)(5)(I) Exhibit (a)(5)(i) NOTICE TO HOLDERS OF THE 1.50% CONVERTIBLE SENIOR NOTES DUE 2018 (CUSIP NO. 05334D AA5) ISSUED BY AUXILIUM PHARMACEUTICALS, INC. NOTICE IS HEREBY GIVEN pursuant to the terms and conditions of the Indenture, dated as of January 30, 2013 (the “Base Indenture”), between Auxilium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Wells Fargo Bank, Nati |
|
| February 3, 2015 |
EX-99.(d)(3) Exhibit (d)(3) EXECUTION COPY AUXILIUM PHARMACEUTICALS, INC., ENDO INTERNATIONAL PLC AND WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee Second Supplemental Indenture Dated as of January 29, 2015 to Indenture Dated as of January 30, 2013 1.50% Convertible Senior Notes due 2018 SECOND SUPPLEMENTAL INDENTURE dated as of January 29, 2015 (this “Supplemental Indenture”), among Auxilium |
|
| February 3, 2015 |
EX-99.(a)(1) Exhibit (a)(1) FUNDAMENTAL CHANGE PURCHASE RIGHT NOTICE, NOTICE OF RIGHT TO CONVERT AND NOTICE OF ENTRY INTO SUPPLEMENTAL INDENTURE AND OFFER TO PURCHASE TO HOLDERS OF 1.50% CONVERTIBLE SENIOR NOTES DUE 2018 ISSUED BY AUXILIUM PHARMACEUTICALS, INC. CUSIP NUMBER: 05334D AA5 NOTICE IS HEREBY GIVEN pursuant to the terms and conditions of the Indenture, dated as of January 30, 2013 (the “ |
|
| February 3, 2015 |
EX-99.(a)(5)(ii) Exhibit (a)(5)(ii) For Immediate Release CONTACTS: Investors/Media: Investors: Media: Keri Mattox Jonathan Neely Heather Zoumas-Lubeski (484) 216-7912 (484) 216-6645 (484) 216-6829 Auxilium Announces Fundamental Change and Make-Whole Fundamental Change Relating to Outstanding Convertible Senior Notes CHESTERBROOK, Pa., Feb. 3, 2015—Auxilium Pharmaceuticals, Inc. (“Auxilium”) today |
|
| January 30, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No. |
|
| January 30, 2015 |
EX-4.1 Exhibit 4.1 EXECUTION COPY AUXILIUM PHARMACEUTICALS, INC., ENDO INTERNATIONAL PLC AND WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee Second Supplemental Indenture Dated as of January 29, 2015 to Indenture Dated as of January 30, 2013 1.50% Convertible Senior Notes due 2018 SECOND SUPPLEMENTAL INDENTURE dated as of January 29, 2015 (this “Supplemental Indenture”), among Auxilium Pharmace |
|
| January 29, 2015 |
CERTIFICATE OF INCORPORATION AUXILIUM PHARMACEUTICALS, INC. EX-3.1 Exhibit 3.1 CERTIFICATE OF INCORPORATION OF AUXILIUM PHARMACEUTICALS, INC. FIRST: The name of the corporation is Auxilium Pharmaceuticals, Inc. (the “Corporation”). SECOND: The address of its registered office in Delaware is 1209 Orange Street in the City of Wilmington, County of New Castle, 19801. The name of the registered agent at such address is The Corporation Trust Company. THIRD: The |
|
| January 29, 2015 |
BY-LAWS AUXILIUM PHARMACEUTICALS, INC. (hereinafter called the “Corporation”) ARTICLE I EX-3.2 Exhibit 3.2 BY-LAWS OF AUXILIUM PHARMACEUTICALS, INC. (hereinafter called the “Corporation”) ARTICLE I OFFICES Section 1. The registered office shall be in Wilmington, Delaware. Section 2. The Corporation may also have offices at such other places both within and without Delaware as the board of directors may from time to time determine or the business of the Corporation may require. ARTICL |
|
| January 29, 2015 |
AUXL / Auxilium Pharmaceuticals Inc S-8 POS - - S-8 POS 333-135347 As filed with the Securities and Exchange Commission on January 29, 2015 Registration No. |
|
| January 29, 2015 |
AUXL / Auxilium Pharmaceuticals Inc S-8 POS - - S-8 POS 333-175238 As filed with the Securities and Exchange Commission on January 29, 2015 Registration No. |
|
| January 29, 2015 |
AUXL / Auxilium Pharmaceuticals Inc POS AM - - POS AM 333-127489 POS AM 1 d859045dposam.htm POS AM 333-127489 As filed with the Securities and Exchange Commission on January 29, 2015 Registration No. 333-127489 Registration No. 333-133477 Registration No. 333-135344 Registration No. 333-145710 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-127489 FORM S-3 REGISTRA |
|
| January 29, 2015 |
AUXL / Auxilium Pharmaceuticals Inc S-8 POS - - S-8 POS 333-117595 S-8 POS 1 d859041ds8pos.htm S-8 POS 333-117595 As filed with the Securities and Exchange Commission on January 29, 2015 Registration No. 333-117595 Registration No. 333-135347 Registration No. 333-144452 Registration No. 333-159867 Registration No. 333-167776 Registration No. 333-175238 Registration No. 333-182943 Registration No. 333-198880 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washing |
|
| January 29, 2015 |
AUXL / Auxilium Pharmaceuticals Inc S-8 POS - - S-8 POS 333-198880 S-8 POS 1 d859041ds8pos.htm S-8 POS 333-198880 As filed with the Securities and Exchange Commission on January 29, 2015 Registration No. 333-117595 Registration No. 333-135347 Registration No. 333-144452 Registration No. 333-159867 Registration No. 333-167776 Registration No. 333-175238 Registration No. 333-182943 Registration No. 333-198880 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washing |
|
| January 29, 2015 |
AUXL / Auxilium Pharmaceuticals Inc S-8 POS - - S-8 POS 333-159867 S-8 POS 1 d859041ds8pos.htm S-8 POS 333-159867 As filed with the Securities and Exchange Commission on January 29, 2015 Registration No. 333-117595 Registration No. 333-135347 Registration No. 333-144452 Registration No. 333-159867 Registration No. 333-167776 Registration No. 333-175238 Registration No. 333-182943 Registration No. 333-198880 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washing |
|
| January 29, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 29, 2015 Auxilium Pharmaceuticals, Inc. |
|
| January 29, 2015 |
AUXL / Auxilium Pharmaceuticals Inc POS AM - - POS AM 333-145710 POS AM 1 d859045dposam.htm POS AM 333-145710 As filed with the Securities and Exchange Commission on January 29, 2015 Registration No. 333-127489 Registration No. 333-133477 Registration No. 333-135344 Registration No. 333-145710 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-127489 FORM S-3 REGISTRA |
|
| January 29, 2015 |
AUXL / Auxilium Pharmaceuticals Inc S-8 POS - - S-8 POS 333-182943 S-8 POS 1 d859041ds8pos.htm S-8 POS 333-182943 As filed with the Securities and Exchange Commission on January 29, 2015 Registration No. 333-117595 Registration No. 333-135347 Registration No. 333-144452 Registration No. 333-159867 Registration No. 333-167776 Registration No. 333-175238 Registration No. 333-182943 Registration No. 333-198880 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washing |
|
| January 29, 2015 |
AUXL / Auxilium Pharmaceuticals Inc POS AM - - POS AM 333-135344 As filed with the Securities and Exchange Commission on January 29, 2015 Registration No. |
|
| January 29, 2015 |
AUXL / Auxilium Pharmaceuticals Inc S-8 POS - - S-8 POS 333-144452 S-8 POS 1 d859041ds8pos.htm S-8 POS 333-144452 As filed with the Securities and Exchange Commission on January 29, 2015 Registration No. 333-117595 Registration No. 333-135347 Registration No. 333-144452 Registration No. 333-159867 Registration No. 333-167776 Registration No. 333-175238 Registration No. 333-182943 Registration No. 333-198880 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washing |
|
| January 29, 2015 |
AUXL / Auxilium Pharmaceuticals Inc POSASR - - POSASR 333-186157 POSASR 1 d859043dposasr.htm POSASR 333-186157 As filed with the Securities and Exchange Commission on January 29, 2015 Registration No. 333-186157 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-186157 UNDER THE SECURITIES ACT OF 1933 AUXILIUM PHARMACEUTICALS, INC. (Exact Name of Registrant as Specifi |
|
| January 29, 2015 |
AUXL / Auxilium Pharmaceuticals Inc S-8 POS - - S-8 POS 333-167776 S-8 POS 1 d859041ds8pos.htm S-8 POS 333-167776 As filed with the Securities and Exchange Commission on January 29, 2015 Registration No. 333-117595 Registration No. 333-135347 Registration No. 333-144452 Registration No. 333-159867 Registration No. 333-167776 Registration No. 333-175238 Registration No. 333-182943 Registration No. 333-198880 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washing |
|
| January 29, 2015 |
AUXL / Auxilium Pharmaceuticals Inc POS AM - - POS AM 333-133477 POS AM 1 d859045dposam.htm POS AM 333-133477 As filed with the Securities and Exchange Commission on January 29, 2015 Registration No. 333-127489 Registration No. 333-133477 Registration No. 333-135344 Registration No. 333-145710 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-127489 FORM S-3 REGISTRA |
|
| January 29, 2015 |
EX-4.1 Exhibit 4.1 EXECUTION COPY AUXILIUM PHARMACEUTICALS, INC., ENDO INTERNATIONAL PLC AND WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee Second Supplemental Indenture Dated as of January 29, 2015 to Indenture Dated as of January 30, 2013 1.50% Convertible Senior Notes due 2018 SECOND SUPPLEMENTAL INDENTURE dated as of January 29, 2015 (this “Supplemental Indenture”), among Auxilium Pharmace |
|
| January 27, 2015 |
AUXILIUM ANNOUNCES RESULTS FROM SPECIAL MEETING OF STOCKHOLDERS Exhibit 99.1 AUXILIUM ANNOUNCES RESULTS FROM SPECIAL MEETING OF STOCKHOLDERS Chesterbrook, PA, January 27, 2015 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, announced that it held a special meeting of its stockholders today at 8:30 a.m. ET to approve matters relating to the previously announced proposed merger with Endo International plc. The proposal to |
|
| January 27, 2015 |
8-K 1 a15-320918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 27, 2015 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware 000-50855 23-3016883 (State or Other (Commission File |
|
| January 26, 2015 |
SC 13G/A 1 auxiliumphceutical12312014.htm AUXILIUM PHARMACEUTICALS INC 12312014 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13D-1(b) AND AMENDMENTS FILED THERETO FILED PURSUANT TO RULE 13D-2(b) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Auxilium Pharmaceuticals Inc. (Name |
|
| January 21, 2015 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 8-K 425 1 a15-267028k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 20, 2015 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware 000-50855 23-3016883 (State or Other Jurisdiction of I |
|
| January 21, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 20, 2015 Auxilium Pharmaceuticals, Inc. |
|
| January 20, 2015 |
ENDP / Endo International plc 425 - Merger Prospectus - FORM 8-K 425 1 d854045d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): January 16, 2015 ENDO INTERNATIONAL PLC (Exact name of registrant as specified in its charter) Ireland 001-36326 Not Applicable (State or other juris |
|
| January 16, 2015 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 8-K 425 1 a15-267018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 16, 2015 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000 |
|
| January 16, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 16, 2015 Auxilium Pharmaceuticals, Inc. |
|
| January 9, 2015 |
ENDP / Endo International plc 425 - Merger Prospectus - FORM 425 Form 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following message was sent to Endo employees on January 9, 2015: Internal CEO Email Memo To: All Endo Empl |
|
| January 9, 2015 |
ENDP / Endo International plc 425 - Merger Prospectus - FORM 425 Form 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following press release was issued by Endo on January 9, 2015: For Immediate Release CONTACT: Investors/Me |
|
| December 24, 2014 |
AUXL / Auxilium Pharmaceuticals Inc DEFM14A - - DEFM14A DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 22, 2014 |
Exhibit 99.1 PRESS RELEASE Chesterbrook, Pa., USA and Stockholm, Sweden, 22 December, 2014 Sobi’s Xiapex receives positive opinion by CHMP for the treatment of Peyronie’s disease Swedish Orphan Biovitrum AB (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a posi |
|
| December 22, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 22, 2014 Auxilium Pharmaceuticals, Inc. |
|
| December 19, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-265382425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. Commission File No.: 000-50855 Date: December 19, 2014 As contemplated by the Amended and Restated Agreement and Plan of Merger, dated November 17, |
|
| December 19, 2014 |
8-K 1 a14-2653818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in its Charter) Delaware 000-50855 23-3016883 (State or Other (Commission |
|
| December 16, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 1 d838963d425.htm 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following message was sent to Endo employees on December 16, 2014: Internal Endo CEO Emai |
|
| December 16, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-263112425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. SEC File No.: 000-50855 Date: December 16, 2014 [Email announcement to employees] To: Auxilium Employees From: Adrian Ada |
|
| December 16, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - FORM 425 Form 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following message was sent to Auxilium employees on December 16, 2014: Endo CEO Email to All Auxilium Empl |
|
| December 16, 2014 |
8-K 1 a14-2631118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 16, 2014 Auxilium Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporati |
|
| December 12, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following press release was issued by Endo on December 11, 2014: For Immediate Release For Immediate Release CO |
|
| December 12, 2014 |
Auxilium Announces Date for Special Meeting of Stockholders Exhibit 99.1 For Immediate Release AUXILIUM CONTACTS: Keri P. Mattox (484) 321-5900 Nichol L. Ochsner (484) 321-5900 Auxilium Announces Date for Special Meeting of Stockholders CHESTERBROOK, Pa., Dec. 11, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that it has scheduled a special meeting of its stockholders for 8:30 a.m. ET on Tuesday, January 27, 2015 to approve matters r |
|
| December 12, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 11, 2014 Auxilium Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-50855 (Commission F |
|
| December 12, 2014 |
Auxilium Announces Date for Special Meeting of Stockholders Exhibit 99.1 For Immediate Release AUXILIUM CONTACTS: Keri P. Mattox (484) 321-5900 Nichol L. Ochsner (484) 321-5900 Auxilium Announces Date for Special Meeting of Stockholders CHESTERBROOK, Pa., Dec. 11, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that it has scheduled a special meeting of its stockholders for 8:30 a.m. ET on Tuesday, January 27, 2015 to approve matters r |
|
| December 12, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 11, 2014 Auxilium Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-50855 (Commission F |
|
| December 3, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 1 d831843d425.htm 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following presentation was given to Capital Research Global Investors on December 3, 2014 |
|
| November 20, 2014 |
Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. PRESENTS XIAFLEX FOR PEYRONIE’S DISEASE DATA AT SMSNA SCIENTIFIC MEETING Peyronie’s Disease Data Presented Enable a Better Understanding of the Safety and Efficacy of XIAFLEX for Treatment of PD; First Data Presented on PD Treatment Impact on Female Partner Sexual Function CHESTERBROOK, Pa., November 20, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUX |
|
| November 20, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 20, 2014 Auxilium Pharmaceuticals, Inc. |
|
| November 20, 2014 |
EX-99.1 2 a14-247754ex99d1.htm EX-99.1 Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. PRESENTS STENDRA DATA AT SMSNA SCIENTIFIC MEETING Erectile Dysfunction Data Presented in Two Moderated Posters; Findings Enable a Better Understanding of the STENDRA Clinical Profile and Provide Additional Data Regarding the Use of STENDRA as Early as Approximately 15 Minutes Before Sexual Activity CHESTERBROOK, Pa. |
|
| November 20, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a14-2477538k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 20, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-5 |
|
| November 19, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K 1 a14-2477518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 18, 2014 Auxilium Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporati |
|
| November 19, 2014 |
EX-99.1 2 a14-247751ex99d1.htm EX-99.1 Exhibit 99.1 For Immediate Release ENDO CONTACTS: AUXILIUM CONTACTS: Investors/Media: Keri P. Mattox Blaine Davis (484) 321-5900 +353-1-268-2001 (484) 216-7158 Nichol L. Ochsner (484) 321-5900 Investors: Jonathan Neely (484) 216-6645 Media: Heather Zoumas-Lubeski (484) 216-6829 Endo Announces Early Termination of HSR Act Waiting Period in Connection with its |
|
| November 19, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2014 Auxilium Pharmaceuticals, Inc. |
|
| November 19, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 1 d824200d425.htm 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following press release was issued by Endo and Auxilium on November 19, 2014: For Immedia |
|
| November 19, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-247752425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. SEC File No.: 000-50855 Date: November 19, 2014 [Email announcement to employees] To: Auxilium Employees From: Adrian Ada |
|
| November 19, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 8-K 425 1 a14-2477558k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-50 |
|
| November 19, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 8-K 425 1 a14-2477518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 18, 2014 Auxilium Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporati |
|
| November 19, 2014 |
EX-99.1 2 a14-247751ex99d1.htm EX-99.1 Exhibit 99.1 For Immediate Release ENDO CONTACTS: AUXILIUM CONTACTS: Investors/Media: Keri P. Mattox Blaine Davis (484) 321-5900 +353-1-268-2001 (484) 216-7158 Nichol L. Ochsner (484) 321-5900 Investors: Jonathan Neely (484) 216-6645 Media: Heather Zoumas-Lubeski (484) 216-6829 Endo Announces Early Termination of HSR Act Waiting Period in Connection with its |
|
| November 18, 2014 |
8-K 1 a14-2373738k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 17, 2014 Auxilium Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporati |
|
| November 18, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 17, 2014 Auxilium Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-50855 (Commission F |
|
| November 12, 2014 |
Entry into a Material Definitive Agreement 8-K 1 a14-2373728k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-50 |
|
| November 6, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following is a transcript of the Endo earnings call held on November 5, 2014: THOMSON REUTERS STREETEVENTS EDITED T |
|
| November 5, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. SEC File No.: 000-50855 Date: November 5, 2014 [Email announcement to employees] To: Auxilium Employees From: Adrian Adams Date: November 5, 2014 Sub |
|
| November 5, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 1 d817941d425.htm 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following slides were used during Endo’s presentation of earnings for the third quarter o |
|
| November 3, 2014 |
Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. TO PRESENT XIAFLEX AND STENDRA DATA AT SMSNA SCIENTIFIC MEETING Multiple Presentations Designed to Enable a Better Understanding of the Safety and Efficacy Profile of XIAFLEX for Treatment of Peyronie’s Disease Additional Onset of Effect Study Results Expand Understanding of STENDRA for Treatment of Erectile Dysfunction CHESTERBROOK, Pa., November 3, 201 |
|
| November 3, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2014 Auxilium Pharmaceuticals, Inc. |
|
| October 30, 2014 |
SEPARATION AGREEMENT AND GENERAL RELEASE Exhibit 10.4 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (the “Agreement and Release”) is being entered into by and between Auxilium Pharmaceuticals, Inc. (hereinafter “Auxilium” or the “Company”), and James E. Fickenscher (“Executive”). WHEREAS, Executive and Auxilium are parties to that certain Amended and Restated Employment Agreement having an effecti |
|
| October 30, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2014 Auxilium Pharmaceuticals, Inc. |
|
| October 30, 2014 |
EMPLOYMENT AGREEMENT (Andrew Saik) EX-10.3 2 a14-198431ex10d3.htm EX-10.3 Exhibit 10.3 EMPLOYMENT AGREEMENT (Andrew Saik) THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into this 8th day of August, 2014, by and between Auxilium Pharmaceuticals, Inc. (the “Company”) and Andrew Saik (“Executive”). WHEREAS, the Company desires to employ Executive as its Chief Financial Officer on the terms and conditions set forth in this Agr |
|
| October 30, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| October 30, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-233153425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. SEC File No.: 000-50855 Date: October 30, 2014 AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2014 FINANCIAL RESU |
|
| October 30, 2014 |
Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2014 FINANCIAL RESULTS $109.6 Million in 3Q 2014 Net Revenues Driven by Strong XIAFLEX Growth; Company Returns to Profitability with 3Q Non-GAAP EPS of $0.27 per Share CHESTERBROOK, Pa., October 30, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financi |
|
| October 29, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 1 d812074d425.htm 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following message was sent to Endo employees on October 29, 2014: TO: All Endo Pharma, En |
|
| October 29, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-233151425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. SEC File No.: 000-50855 Date: October 29, 2014 [Email announcement to employees] To: Auxilium Employees From: Adrian Adam |
|
| October 21, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 20, 2014 Auxilium Pharmaceuticals, Inc. |
|
| October 21, 2014 |
EX-99.1 2 a14-227231ex99d1.htm EX-99.1 Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES XIAFLEX NOW APPROVED FOR THE CONCURRENT TREATMENT OF UP TO TWO AFFECTED JOINTS IN THE SAME HAND IN DUPUYTREN’S CONTRACTURE PATIENTS Estimated 35-40 Percent of Surgical Procedures to Treat DC Have Been Performed on Multiple Joints CHESTERBROOK, Pa., October 20, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: |
|
| October 15, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 1 d805025d425.htm 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following slides were used in connection with a presentation to employees on October 15, |
|
| October 10, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following slides were used in connection with a presentation to employees on October 10, 2014: Rajiv De Silva P |
|
| October 9, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following message was sent to Endo partners on October 9, 2014: As you are a valued strategic partner of Endo, I am |
|
| October 9, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 1 d802418d425.htm 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following fact sheet was made available to, among others, Endo employees and representati |
|
| October 9, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-222147425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. Commission File No.: 000-50855 Date: October 9, 2014 ENDO CONTACTS: AUXILIUM CONTACTS: Investors/Media: Keri P. Mattox Blaine Davis (484) 321-5900 |
|
| October 9, 2014 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AMONG AUXILIUM PHARMACEUTICALS, INC. AND ENDO INTERNATIONAL PLC AND ENDO U.S. INC. AND AVALON MERGER SUB INC. October 8, 2014 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Currency 20 1.3 Interpretation Not Affected by Headings 20 1.4 Knowledge and Disclosure 20 1.5 Extended Meanings, Etc. 20 1.6 Date of Any Action 21 |
|
| October 9, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 1 d802418d425.htm 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following is a transcript of the Endo Investor Presentation held on October 9, 2014: THOM |
|
| October 9, 2014 |
EX-99.1 Exhibit 99.1 ENDO CONTACTS: Investors/Media: Blaine Davis +353-1-691-7579 (484) 216-7158 Investors: Jonathan Neely (484) 216-6645 Media: Heather Zoumas-Lubeski (484) 216-6829 Media: Andy Brimmer / Kelly Sullivan / Aaron Palash Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449 AUXILIUM CONTACTS: Keri P. Mattox (484) 321-5900 Nichol L. Ochsner (484) 321-5900 ENDO TO ACQUIRE AUXILIUM PHAR |
|
| October 9, 2014 |
Auxilium Pharmaceuticals, Inc. 640 Lee Road Chesterbrook, PA 19087 Exhibit 10.2 Auxilium Pharmaceuticals, Inc. 640 Lee Road Chesterbrook, PA 19087 October 8, 2014 VIA FACSIMILE AND COURIER QLT Inc. 887 Great Northern Way, Suite 250 Vancouver, BC V5T 4T5 Canada Attn: Dori Assaly Facsimile No.: (604) 873-0816 E-mail: [email protected] Re: Notice of Termination Dear Dori: Reference is made to the Agreement and Plan of Merger, dated as of June 25, 2014 (the “Merger |
|
| October 9, 2014 |
FIRST AMENDMENT TO RIGHTS AGREEMENT Exhibit 10.1 Execution Version FIRST AMENDMENT TO RIGHTS AGREEMENT This FIRST AMENDMENT TO RIGHTS AGREEMENT dated as of October 8, 2014 (this “Amendment”) is entered into by and between Auxilium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Broadridge Corporate Issuer Solutions, Inc. (the “Rights Agent”). Capitalized terms used but not defined herein shall have the respective |
|
| October 9, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 1 d802418d425.htm 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following message was sent to Endo employees on October 9, 2014: TO: All Endo, EPI, AMS, |
|
| October 9, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-222143425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. Commission File No.: 000-50855 Date: October 9, 2014 Employee Nano Meeting Overview Auxilium & Endo October 9, 2014 Agenda: Employee Nano Meeting P |
|
| October 9, 2014 |
FIRST AMENDMENT TO RIGHTS AGREEMENT Exhibit 10.1 Execution Version FIRST AMENDMENT TO RIGHTS AGREEMENT This FIRST AMENDMENT TO RIGHTS AGREEMENT dated as of October 8, 2014 (this “Amendment”) is entered into by and between Auxilium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Broadridge Corporate Issuer Solutions, Inc. (the “Rights Agent”). Capitalized terms used but not defined herein shall have the respective |
|
| October 9, 2014 |
Exhibit 99.1 ENDO CONTACTS: AUXILIUM CONTACTS: Investors/Media: Keri P. Mattox Blaine Davis (484) 321-5900 +353-1-691-7579 (484) 216-7158 Nichol L. Ochsner (484) 321-5900 Investors: Jonathan Neely (484) 216-6645 Media: Heather Zoumas-Lubeski (484) 216-6829 Media: Andy Brimmer / Kelly Sullivan / Aaron Palash Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449 ENDO TO ACQUIRE AUXILIUM PHARMACEUTIC |
|
| October 9, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-222145425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. Commission File No.: 000-50855 Date: October 9, 2014 Endo and Auxilium: October 9, 2014 A Compelling Business Combination ADDITIONAL INFORMATION Th |
|
| October 9, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-222144425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. Commission File No.: 000-50855 Date: October 9, 2014 ENDO CONTACTS: AUXILIUM CONTACTS: Investors/Media: Keri P. Mattox Blaine Davis (484) 321-5900 |
|
| October 9, 2014 |
Auxilium Pharmaceuticals, Inc. 640 Lee Road Chesterbrook, PA 19087 Exhibit 10.2 Auxilium Pharmaceuticals, Inc. 640 Lee Road Chesterbrook, PA 19087 October 8, 2014 VIA FACSIMILE AND COURIER QLT Inc. 887 Great Northern Way, Suite 250 Vancouver, BC V5T 4T5 Canada Attn: Dori Assaly Facsimile No.: (604) 873-0816 E-mail: [email protected] Re: Notice of Termination Dear Dori: Reference is made to the Agreement and Plan of Merger, dated as of June 25, 2014 (the “Merger |
|
| October 9, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 8-K 425 1 a14-2221418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 8, 2014 Auxilium Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50855 23-3016883 (State or Other Jurisdic |
|
| October 9, 2014 |
Exhibit 99.1 ENDO CONTACTS: AUXILIUM CONTACTS: Investors/Media: Keri P. Mattox Blaine Davis (484) 321-5900 +353-1-691-7579 (484) 216-7158 Nichol L. Ochsner (484) 321-5900 Investors: Jonathan Neely (484) 216-6645 Media: Heather Zoumas-Lubeski (484) 216-6829 Media: Andy Brimmer / Kelly Sullivan / Aaron Palash Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449 ENDO TO ACQUIRE AUXILIUM PHARMACEUTIC |
|
| October 9, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following message was sent to Endo customers on October 9, 2014: As you are a valued customer of Endo, I am writing |
|
| October 9, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-222146425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. Commission File No.: 000-50855 Date: October 9, 2014 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT ENDP - Endo International Plc Conference Call t |
|
| October 9, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 8, 2014 Auxilium Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50855 23-3016883 (State or Other Jurisdiction of Incorporation) (Com |
|
| October 9, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): October 8, 2014 ENDO INTERNATIONAL PLC (Exact name of registrant as specified in its charter) Ireland 001-36326 Not Applicable (State or other jurisdiction of incorporation or |
|
| October 9, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 1 d802418d425.htm 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following message was sent to Endo’s research and development employees on October 9, 201 |
|
| October 9, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 1 d802418d425.htm 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following voicemail was delivered to Endo’s sales force on October 9, 2014: Sales Force V |
|
| October 9, 2014 |
©2014 Endo Pharmaceuticals Inc. All rights reserved. EX-99.2 ©2014 Endo Pharmaceuticals Inc. All rights reserved. ©2014 Endo Pharmaceuticals Inc. All rights reserved. Endo and Auxilium: October 9, 2014 A Compelling Business Combination Exhibit 99.2 ©2014 Endo Pharmaceuticals Inc. All rights reserved. 2 Additional Information ADDITIONAL INFORMATION This communication does not constitute an offer to buy or solicitation of an offer to sell any securiti |
|
| October 9, 2014 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AMONG AUXILIUM PHARMACEUTICALS, INC. AND ENDO INTERNATIONAL PLC AND ENDO U.S. INC. AND AVALON MERGER SUB INC. October 8, 2014 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Currency 20 1.3 Interpretation Not Affected by Headings 20 1.4 Knowledge and Disclosure 20 1.5 Extended Meanings, Etc. 20 1.6 Date of Any Action 21 1.7 Schedul |
|
| October 9, 2014 |
EX-2.1 2 a14-222141ex2d1.htm EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AMONG AUXILIUM PHARMACEUTICALS, INC. AND ENDO INTERNATIONAL PLC AND ENDO U.S. INC. AND AVALON MERGER SUB INC. October 8, 2014 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Currency 20 1.3 Interpretation Not Affected by Headings 20 1.4 Knowledge and Disclosure 20 1.5 Extended Meanings |
|
| October 9, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-222142425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. Commission File No.: 000-50855 Date: October 9, 2014 [Email announcement to employees] To: Auxilium Employees From: Adrian Adams Date: October 9, 2 |
|
| September 22, 2014 |
Exhibit 10.1 EXECUTION VERSION $50,000,000 INCREMENTAL TERM LOAN FACILITY INCREMENTAL ASSUMPTION AGREEMENT dated as of September 22, 2014 among AUXILIUM PHARMACEUTICALS, INC., as Borrower SUBSIDIARIES OF THE BORROWER PARTY HERETO, THE INCREMENTAL TERM LOAN LENDERS PARTY HERETO and MORGAN STANLEY SENIOR FUNDING, INC., as Administrative Agent MORGAN STANLEY SENIOR FUNDING, INC., as Sole Lead Arrange |
|
| September 22, 2014 |
AUXL / Auxilium Pharmaceuticals Inc S-8 - - S-8 S-8 1 a14-212751s8.htm S-8 As filed with the Securities and Exchange Commission on September 22, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AUXILIUM PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 23-3016883 (State or Other Jurisdiction of Inc |
|
| September 22, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-1725012425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. SEC File No.: 000-50855 Date: September 22, 2014 [Email announcement to employees] To: Auxilium Employees From: Adrian A |
|
| September 22, 2014 |
AUXILIUM PROVIDES TRANSACTION UPDATE Board Unanimously Reaffirms Recommendation of QLT Transaction Exhibit 99.1 AUXILIUM PROVIDES TRANSACTION UPDATE Board Unanimously Reaffirms Recommendation of QLT Transaction Chesterbrook, PA, September 22, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that its Board of Directors (the “Board”) has reviewed the unsolicited, non-binding and conditional proposal from Endo International plc (“Endo”) a |
|
| September 22, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 1 d793163d425.htm 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 000-50855) The following press release was issued by Endo on September 22, 2014: CONTACT: Investors/Medi |
|
| September 22, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 22, 2014 Auxilium Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50855 23-3016883 (State or Other Jurisdiction of Incorporation) ( |
|
| September 22, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 22, 2014 Auxilium Pharmaceuticals, Inc. |
|
| September 22, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-1725013425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. SEC File No.: 000-50855 Date: September 22, 2014 AUXILIUM PROVIDES TRANSACTION UPDATE Board Unanimously Reaffirms Recomm |
|
| September 18, 2014 |
Joint Filer Information Names: Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P. Address: 780 Third Avenue, 37th Floor New York, NY 10017 Designated Filer: James E. Flynn Issuer and Ticker Symbol: Auxilium Pharmaceuticals, Inc. [AUXL] Date of Earliest Transaction Reported: June 6, 2014 The undersigned, Deerfield Mgmt, L.P. |
|
| September 18, 2014 |
Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. PRESENTS XIAFLEX (CCH) DATA FROM MULTICORD AND RETREATMENT STUDIES AT THE ASSH ANNUAL MEETING Data Support CCH could be Used to Treat Two Affected Joints Concurrently; Positive Results Presented from Additional Studies Evaluating CCH Retreatment for Recurrent Contracture CHESTERBROOK, Pa., September 18, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL |
|
| September 18, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a14-2108338k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 18, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000- |
|
| September 18, 2014 |
Exhibit 99.1 VIVUS AND AUXILIUM ANNOUNCE FDA APPROVAL OF STENDRA sNDA; STENDRA NOW FIRST AND ONLY ORAL ERECTILE DYSFUNCTION TREATMENT APPROVED TO BE TAKEN APPROXIMATELY 15 MINUTES BEFORE SEXUAL ACTIVITY MOUNTAIN VIEW, Calif. and CHESTERBROOK, Pa., September 18, 2014 — VIVUS, Inc. (NASDAQ: VVUS) and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that the U.S. Food and Drug Administra |
|
| September 18, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 18, 2014 Auxilium Pharmaceuticals, Inc. |
|
| September 17, 2014 |
Exhibit 4.1 AUXILIUM PHARMACEUTICALS, INC. and BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC. as Rights Agent RIGHTS AGREEMENT Dated as of September 17, 2014 TABLE OF CONTENTS Page Section 1. Certain Definitions 2 Section 2. Appointment of Rights Agent 7 Section 3. Issuance of Rights Certificates 7 Section 4. Form of Rights Certificates 9 Section 5. Countersignature and Registration 9 Section 6. Tran |
|
| September 17, 2014 |
Exhibit 3.1 CERTIFICATE OF DESIGNATION, PREFERENCES AND RIGHTS OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK (Par Value $0.01 Per Share) OF AUXILIUM PHARMACEUTICALS, INC. (Pursuant to Section 151 of the General Corporation Law of the State of Delaware) I, the undersigned, being the Chief Administrative Officer, General Counsel and Secretary of AUXILIUM PHARMACEUTICALS, INC., a corporation organ |
|
| September 17, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 16, 2014 Auxilium Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-50855 (Commission |
|
| September 17, 2014 |
Exhibit 99.1 AUXILIUM RESPONDS TO UNSOLICITED PROPOSAL FROM ENDO INTERNATIONAL Adopts One Year Stockholder Rights Plan Chesterbrook, PA, September 17, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today confirmed that Auxilium has received an unsolicited, non-binding proposal from Endo International plc (NASDAQ: ENDP) to acquire all of the outstanding |
|
| September 17, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-210832425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. SEC File No.: 000-50855 Date: September 17, 2014 AUXILIUM RESPONDS TO UNSOLICITED PROPOSAL FROM ENDO INTERNATIONAL Adopts |
|
| September 17, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 8-A12B - - 8-A12B 8-A12B 1 a14-2108358a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES AND EXCHANGE ACT OF 1934 PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Auxilium Pharmaceuticals, Inc (Exact name of registrant as specified in its charter) |
|
| September 17, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 000-50855) The following is a transcript of the Endo Investor Presentation held on September 16, 2014: THOMSON REUTERS STREETE |
|
| September 16, 2014 |
ENDO DELIVERS A PROPOSAL TO ACQUIRE AUXILIUM PHARMACEUTICALS FOR $28.10 PER SHARE IN CASH AND STOCK EX-99.1 Exhibit 99.1 CONTACT: Investors/Media: Media: Blaine Davis +353-1-691-7579 Heather Zoumas-Lubeski (484) 216-6829 Investors: Jonathan Neely (484) 216-6645 Media: Andy Brimmer / Kelly Sullivan / Aaron Palash Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449 ENDO DELIVERS A PROPOSAL TO ACQUIRE AUXILIUM PHARMACEUTICALS FOR $28.10 PER SHARE IN CASH AND STOCK • Endo’s Proposal Provides Auxil |
|
| September 16, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 000-50855) The following presentation is to be used during Endo’s investor presentation on September 16, 2014: Endo Auxilium: |
|
| September 16, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - 425 425 Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 000-50855) The following message was sent to Endo employees on September 16, 2014: TO: All Endo, EPI, AMS, Qualitest, Paladin, |
|
| September 16, 2014 |
ENDP / Endo International plc 425 - Merger Prospectus - FORM 8-K 425 1 d790123d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): September 16, 2014 ENDO INTERNATIONAL PLC (Exact name of registrant as specified in its charter) Ireland 001-36326 Not Applicable (State or other jur |
|
| September 10, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a14-2070728k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 10, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000- |
|
| September 10, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. SEC File No.: 000-50855 Date: September 9, 2014 Morgan Stanley Healthcare Conference Corporate Overview September 10, 2014 Safe Harbor We will make v |
|
| September 10, 2014 |
Morgan Stanley Healthcare Conference Corporate Overview September 10, 2014 Exhibit 99.1 Morgan Stanley Healthcare Conference Corporate Overview September 10, 2014 Safe Harbor We will make various remarks during this presentation that constitute "forward-looking statements" for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding: the Company's expected financial performance, including the degree |
|
| September 9, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-207073425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. SEC File No.: 000-50855 Date: September 9, 2014 AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES CORPORATE RESTRUCTURING DESIGNED |
|
| September 9, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a14-2070718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 9, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-5 |
|
| September 9, 2014 |
Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES CORPORATE RESTRUCTURING DESIGNED TO STREAMLINE OPERATIONS, MAXIMIZE CASH FLOW AND DRIVE SUSTAINABLE EARNINGS GROWTH - Expected to Reduce Annual Operating Expenses by At Least $75 Million - - Focus on Targeted R&D Spend, Consolidated Commercial Operations, Improved Manufacturing Efficiency and Streamlined G&A Expenses — CHESTERBROOK, Pa., Septem |
|
| August 28, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 28, 2014 Auxilium Pharmaceuticals, Inc. |
|
| August 28, 2014 |
Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. TO PRESENT CCH DATA FOR CONCURRENT TREATMENT OF MULTIPLE DUPUYTREN’S CORDS AT ASSH ANNUAL MEETING Study Results of Concurrent CCH Injections to Treat Two Dupuytren’s Contracture Cords with Delayed Finger Extension Selected for Best Paper Session; Data Support Safe and Effective Use of CCH for Treatment of Two Affected Joints Concurrently CHESTERBROOK, Pa |
|
| August 21, 2014 |
8-K 1 a14-1947228k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 15, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-508 |
|
| August 21, 2014 |
Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES POSITIVE DATA FROM PHASE 2A STUDY OF CCH IN PATIENTS WITH CELLULITE Mid and High Level Doses Demonstrate Statistically Significant Improvement in Cellulite Across All Endpoints; Nearly 70% of Mid and High Dose Patients Satisfied or Very Satisfied with Results CHESTERBROOK, Pa., August 21, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a |
|
| August 21, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a14-1947218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 21, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-508 |
|
| August 18, 2014 |
THIRD AMENDMENT AGREEMENT TO CREDIT AGREEMENT Exhibit 10.1 EXECUTION COPY THIRD AMENDMENT AGREEMENT TO CREDIT AGREEMENT THIS THIRD AMENDMENT AGREEMENT (this “Third Amendment Agreement”), dated as of August 14, 2014, is made by and among AUXILIUM PHARMACEUTICALS, INC. (the “Borrower”), the subsidiaries of the Borrower listed on the signature pages hereto (the “Subsidiary Guarantors”; together with the Borrower, the “Loan Parties”), certain Len |
|
| August 18, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 a14-17250118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware 000-50855 23-3016883 (State or Other (Commission File |
|
| August 18, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2014 Auxilium Pharmaceuticals, Inc. |
|
| August 18, 2014 |
THIRD AMENDMENT AGREEMENT TO CREDIT AGREEMENT Exhibit 10.1 EXECUTION COPY THIRD AMENDMENT AGREEMENT TO CREDIT AGREEMENT THIS THIRD AMENDMENT AGREEMENT (this “Third Amendment Agreement”), dated as of August 14, 2014, is made by and among AUXILIUM PHARMACEUTICALS, INC. (the “Borrower”), the subsidiaries of the Borrower listed on the signature pages hereto (the “Subsidiary Guarantors”; together with the Borrower, the “Loan Parties”), certain Len |
|
| August 11, 2014 |
8-K 1 a14-17250108k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-508 |
|
| August 11, 2014 |
AUXILIUM PHARMACEUTICALS, INC. APPOINTS ANDREW SAIK CHIEF FINANCIAL OFFICER Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. APPOINTS ANDREW SAIK CHIEF FINANCIAL OFFICER CHESTERBROOK, Pa., August 11, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, announced that Andrew Saik will be appointed Chief Financial Officer, effective August 18, 2014. Mr. Saik will be responsible for all financial and information technology |
|
| August 11, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. SEC File No.: 000-50855 Date: August 11, 2014 AUXILIUM PHARMACEUTICALS, INC. APPOINTS ANDREW SAIK CHIEF FINANCIAL OFFICER CHESTERBROOK, Pa., August 1 |
|
| August 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 7, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-172506425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. SEC File No.: 000-50855 Date: August 7, 2014 AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2014 FINANCIAL RESUL |
|
| August 7, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-172505425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. SEC File No.: 000-50855 Date: August 7, 2014 Auxilium Pharmaceuticals, Inc | 2014 2Q 2014 Financial Results Corporate Ove |
|
| August 7, 2014 |
SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AUXILIUM PHARMACEUTICALS, INC. Exhibit 3.1 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AUXILIUM PHARMACEUTICALS, INC. Auxilium Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under, and by virtue of, the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. The name of the Corporation is Auxilium Pharmaceuticals, Inc. The date of filing of its original C |
|
| August 7, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-172508425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. SEC File No.: 000-50855 Date: August 7, 2014 EMPLOYEE PRESENTATION 2Q 2014 Financial Results Summit Meeting August 7, 201 |
|
| August 7, 2014 |
SEPARATION AGREEMENT AND GENERAL RELEASE Exhibit 10.2 May 30, 2014 James E. Fickenscher 585 Oakmont Drive East Telford, PA 18969 Dear Jim: The purpose of this letter is to provide you with written notice of termination of your employment and that certain Amended and Restated Employment Agreement by and between you and Auxilium Pharmaceuticals, Inc. (“Auxilium”) dated as of December 19, 2013 (your “Employment Agreement”), effective as of |
|
| August 7, 2014 |
8-K 1 a14-1725048k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-5085 |
|
| August 7, 2014 |
Exhibit 10.1 CONFIDENTIAL EXECUTION VERSION 1% Testosterone Gel DISTRIBUTION AND SUPPLY AGREEMENT by and between Auxilium Pharmaceuticals, Inc. and Prasco, LLC dated April 1, 2014 Confidential treatment requested under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2. The confidential portions of this exhibit have been omitted and are marked accordingly. The confidential portions have been filed separately |
|
| August 7, 2014 |
Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2014 FINANCIAL RESULTS 2Q 2014 Net Revenues of $83.0 Million Driven by Launches of XIAFLEX for Peyronie’s Disease and STENDRA Auxilium Continues Strategic Transformation into Leading North American Specialty Biopharmaceutical Company with QLT Inc. Merger Expected to Close in 4Q 2014 CHESTERBROOK, Pa., August 7, 2014 — Auxilium Ph |
|
| August 7, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-172507425.htm 425 1 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us © 2014 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters a |
|
| August 5, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 8-K 425 1 a14-1725038k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2014 (July 30, 2014) Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other Jurisdiction of Incorpo |
|
| August 5, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2014 (July 30, 2014) Auxilium Pharmaceuticals, Inc. |
|
| July 31, 2014 |
Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES XIAFLEX MILESTONE: PARTNER ASAHI KASEI PHARMA CORPORATION COMPLETES REGULATORY SUBMISSION FOR DUPUYTREN?S CONTRACTURE IN JAPAN Acceptance of Regulatory Submission Triggers $10 Million Milestone Payment to Auxilium CHESTERBROOK, Pa., July 31, 2014 ? Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today annou |
|
| July 31, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2014 Auxilium Pharmaceuticals, Inc. |
|
| July 7, 2014 |
Exhibit 99.1 VOTING AGREEMENT THIS AGREEMENT is dated as of June 25, 2014 (this “Agreement”) BETWEEN: THE PERSONS NAMED ON THE SIGNATURE PAGE HERETO (each such person a “Company Shareholder”) AND: Auxilium Pharmaceuticals, Inc., a corporation incorporated under the laws of Delaware (“Auxilium”). WHEREAS: A. QLT Inc., a corporation incorporated under the laws of British Columbia (the “Company”), Au |
|
| July 7, 2014 |
NVLN / NOVELION THERAPEUTICS INC. / AUXILIUM PHARMACEUTICALS INC - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* QLT INC. (Name of Issuer) Common Shares without par value (Title of Class of Securities) 746927102 (CUSIP Number) Auxilium Pharmaceuticals, Inc. 640 Lee Road Chesterbro |
|
| July 7, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 425 1 a14-167171425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: QLT Inc. SEC File No.: 0-17082 Date: July 7, 2014 Explanatory Note: This article appeared in The Wall Street Journal on July 6, 2014 for the digital edi |
|
| July 7, 2014 |
Exhibit 99.3 VOTING AGREEMENT THIS AGREEMENT is dated as of June 25, 2014 (this “Agreement”) BETWEEN: THE PERSONS NAMED ON THE SIGNATURE PAGE HERETO (each such person a “Company Shareholder”) AND: Auxilium Pharmaceuticals, Inc., a corporation incorporated under the laws of Delaware (“Auxilium”). WHEREAS: A. QLT Inc., a corporation incorporated under the laws of British Columbia (the “Company”), Au |
|
| July 7, 2014 |
Exhibit 99.2 VOTING AGREEMENT THIS AGREEMENT is dated as of June 25, 2014 (this “Agreement”) BETWEEN: THE PERSONS NAMED ON THE SIGNATURE PAGE HERETO (each such person a “Company Shareholder”) AND: Auxilium Pharmaceuticals, Inc., a corporation incorporated under the laws of Delaware (“Auxilium”). WHEREAS: A. QLT Inc., a corporation incorporated under the laws of British Columbia (the “Company”), Au |
|
| June 30, 2014 |
AUXL / Auxilium Pharmaceuticals Inc 425 - Merger Prospectus - 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: QLT Inc. SEC File No.: 0-17082 Date: June 30, 2014 Explanatory Note: This article was posted on www.mergermarket.com on June 27, 2014. QLT’s (TSE:QLT) sale process was driven by an |
|
| June 26, 2014 |
QuickLinks - Click here to rapidly navigate through this document Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AMONG AUXILIUM PHARMACEUTICALS, INC. AND QLT INC. AND QLT HOLDING CORP. AND QLT ACQUISITION CORP. June 25, 2014 TABLE OF CONTENTS Page ARTICLE I INTERPRETATION 1 1.1 Definitions 1 1.2 Currency 15 1.3 Interpretation Not Affected by Headings 15 1.4 Knowledge and Disclosure 15 1.5 Extended Meani |
|
| June 26, 2014 |
QuickLinks - Click here to rapidly navigate through this document Exhibit 10.1 VOTING AGREEMENT THIS AGREEMENT is dated as of June , 2014 (this "Agreement") BETWEEN: THE PERSONS NAMED ON THE SIGNATURE PAGE HERETO (each such person a "Company Shareholder") AND: Auxilium Pharmaceuticals, Inc., a corporation incorporated under the laws of Delaware ("Auxilium"). WHEREAS: A. QLT Inc., a corporation inc |
|
| June 26, 2014 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| June 26, 2014 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| June 26, 2014 |
QuickLinks - Click here to rapidly navigate through this document Exhibit 99.1 Auxilium Pharmaceuticals to Merge with Canadian Biotechnology Company QLT Accelerates Auxilium's Ongoing Transformation Into Leading North American Specialty Biopharmaceutical Company Canadian-Domiciled Structure Creates Stronger Financial Position, Competitive Partnering and M&A Platform Platform Enables Continued Prod |
|
| June 26, 2014 |
425 1 a14-159652425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: QLT Inc. SEC File No.: 0-17082 Date: June 26, 2014 Strategic Transaction Auxilium Merger with QLT June 26, 2014 No Offer or Solicitation This communicat |
|
| June 26, 2014 |
QuickLinks - Click here to rapidly navigate through this document Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AMONG AUXILIUM PHARMACEUTICALS, INC. AND QLT INC. AND QLT HOLDING CORP. AND QLT ACQUISITION CORP. June 25, 2014 TABLE OF CONTENTS Page ARTICLE I INTERPRETATION 1 1.1 Definitions 1 1.2 Currency 15 1.3 Interpretation Not Affected by Headings 15 1.4 Knowledge and Disclosure 15 1.5 Extended Meani |
|
| June 26, 2014 |
425 1 a14-159654425.htm 425 Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: QLT Inc. SEC File No.: 0-17082 Date: June 26, 2014 [Email announcement to employees] To: Auxilium Employees From: Adrian Adams Date: June 26, 2014 Subje |
|
| June 26, 2014 |
Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: QLT Inc. SEC File No.: 0-17082 Date: June 26, 2014 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT AUXL - Auxilium Pharmaceuticals Inc to Merge with QLT Call EVENT DATE/TIME: JUNE 2 |
|
| June 26, 2014 |
QuickLinks - Click here to rapidly navigate through this document Exhibit 99.1 Auxilium Pharmaceuticals to Merge with Canadian Biotechnology Company QLT Accelerates Auxilium's Ongoing Transformation Into Leading North American Specialty Biopharmaceutical Company Canadian-Domiciled Structure Creates Stronger Financial Position, Competitive Partnering and M&A Platform Platform Enables Continued Prod |
|
| June 26, 2014 |
QuickLinks - Click here to rapidly navigate through this document Exhibit 10.1 VOTING AGREEMENT THIS AGREEMENT is dated as of June , 2014 (this "Agreement") BETWEEN: THE PERSONS NAMED ON THE SIGNATURE PAGE HERETO (each such person a "Company Shareholder") AND: Auxilium Pharmaceuticals, Inc., a corporation incorporated under the laws of Delaware ("Auxilium"). WHEREAS: A. QLT Inc., a corporation inc |
|
| June 26, 2014 |
Filed by Auxilium Pharmaceuticals, Inc. (SEC File No.: 000-50855) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: QLT Inc. SEC File No.: 0-17082 Date: June 26, 2014 Strategic Transaction Auxilium Merger with QLT June 26, 2014 Merger Aligned with Growth Strategy Creates PLATFORM Designed to Acc |
|
| June 25, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a14-1519828k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 25, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-50855 |
|
| June 25, 2014 |
SOBI FILES FOR EU APPROVAL OF XIAPEX FOR PEYRONIES DISEASE Exhibit 99.1 SOBI FILES FOR EU APPROVAL OF XIAPEX FOR PEYRONIES DISEASE Stockholm, Sweden and Chesterbrook, Pa., June 25, 2014 — Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. today announced that Sobi has filed for an extension of the label for Xiapex® (collagenase clostridium histolyticum) with the European Medicines Agency (EMA) to include the indication of Peyroni |
|
| June 11, 2014 |
Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES LAUNCH OF AUTHORIZED GENERIC VERSION OF TESTIM (TESTOSTERONE GEL) CHESTERBROOK, Pa., June 11, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC (“Prasco”) to introduce an Authorized Generic version of Testim® (testosterone gel). Pr |
|
| June 11, 2014 |
8-K 1 a14-1519818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware 000-50855 23-3016883 (State or Other Jurisdiction of Inco |
|
| June 10, 2014 |
AUXL / Auxilium Pharmaceuticals Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| June 5, 2014 |
8-K 1 a14-1486518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-50855 |
|
| June 2, 2014 |
AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER CHESTERBROOK, Pa., June 2, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that James E. Fickenscher, Chief Financial Officer, is leaving the Company to pursue other interests. Mr. Fickenscher will continue in his current role thro |
|
| June 2, 2014 |
8-K 1 a14-1453218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 30, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-50855 |
|
| May 22, 2014 |
Submission of Matters to a Vote of Security Holders 8-K 1 a14-1289728k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-50855 |
|
| May 19, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a14-1289718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware 000-50855 23-3016883 (State or Other (Commission File (I. |
|
| May 19, 2014 |
Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. PRESENTS NEW ANALYSES OF XIAFLEX PEYRONIE’S DISEASE DATA AT UROLOGY MEETING Four Podium Sessions Highlight New Analyses of Data Evaluating XIAFLEX for the Treatment of Peyronie’s Disease; CHESTERBROOK, Pa., May 19, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that new analys |
|
| May 5, 2014 |
Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2014 FINANCIAL RESULTS 1Q 2014 Net Revenues Increased 34% Over 1Q 2013 to $88.5 Million on Acquisition Growth and Launch Momentum for STENDRA and XIAFLEX in Peyronie’s Disease CHESTERBROOK, Pa., May 5, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced fina |
|
| May 5, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 5, 2014 |
8-K 1 a14-1186918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware 000-50855 23-3016883 (State or Other Jurisdiction of Incor |
|
| April 30, 2014 |
Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. LOWERS 2014 FINANCIAL GUIDANCE Company to Report Full 1Q 2014 Financial Results on Monday, May 5 CHESTERBROOK, Pa., April 29, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that it is reducing its financial guidance for the full year 2014 due primarily to lower-than-expected r |
|
| April 30, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 29, 2014 Auxilium Pharmaceuticals, Inc. |
|
| April 28, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 28, 2014 Auxilium Pharmaceuticals, Inc. |
|
| April 28, 2014 |
Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES PRESENTATION OF DATA FOR XIAFLEX AT UROLOGY MEETING Four Podium Sessions to Highlight New Analyses of Data from Pivotal Phase 3 Trials Evaluating XIAFLEX for the Treatment of Peyronie’s Disease CHESTERBROOK, Pa., April 28, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announc |
|
| April 14, 2014 |
Exhibit 99.1 AUXILIUM AND SOBI ANNOUNCE ENCORE PRESENTATION OF XIAFLEX/XIAPEX DATA AT EUROPEAN ASSOCIATION OF UROLOGY CONGRESS Encore Data Highlighted from Trials Evaluating XIAFLEX, the First and Only FDA Approved Treatment for Peyronie’s Disease CHESTERBROOK, Pa. and Stockholm, Sweden, April 14, 2013 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Swedish Orphan Biovitrum AB (publ) (Sobi) to |
|
| April 14, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 14, 2014 Auxilium Pharmaceuticals, Inc. |
|
| April 10, 2014 |
DEF 14A 1 a2219570zdef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o |
|
| April 8, 2014 |
PRER14A 1 a2219400zprer14a.htm PRER 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) Amendment No. 1 INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the a |
|
| April 8, 2014 |
CORRESP 1 filename1.htm Auxilium Pharmaceuticals, Inc. Michael J. Purvis Senior Associate General Counsel and Assistant Secretary 640 Lee Road Chesterbrook, PA 19087 (484) 321-5944 [email protected] Auxilium Pharmaceuticals, Inc. File Number 000-50855 Via Edgar April 8, 2014 Mr. Jeffrey P. Riedler Assistant Director United States Securities and Exchange Commission Division of Corporation Financ |
|
| April 7, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a14-1009218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 7, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-50855 |
|
| April 7, 2014 |
SOBI BECOMES MARKET AUTHORISATION HOLDER FOR XIAPEX IN EUROPE Exhibit 99.1 SOBI BECOMES MARKET AUTHORISATION HOLDER FOR XIAPEX IN EUROPE Stockholm, Sweden and Chesterbrook, Pa., April 7, 2014 — Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that Sobi became the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on Apr |
|
| March 27, 2014 |
PRE 14A 1 a14-25841pre14a.htm PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the |
|
| February 28, 2014 |
Exhibit 10.14 Confidential treatment requested under 17 C.F.R. ?? 200.80(b)(4) and 240.24b-2. The confidential portions of this exhibit have been omitted and are marked accordingly. The confidential portions have been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. LICENSE AND COMMERCIALIZATION AGREEMENT dated as of October 10, 2013 by and |
|
| February 28, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2014 Auxilium Pharmaceuticals, Inc. |
|
| February 28, 2014 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT (James E. Fickenscher) Exhibit 10.53 AMENDED AND RESTATED EMPLOYMENT AGREEMENT (James E. Fickenscher) THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into this 19th day of December, 2013 (the ?Effective Date?), by and between Auxilium Pharmaceuticals, Inc. (the ?Company?) and James E. Fickenscher (?Executive?). WHEREAS, the Company and Executive most recently entered into an employment agree |
|
| February 28, 2014 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Jennifer Armstrong) Exhibit 10.54 AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Jennifer Armstrong) THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into this 19th day of December, 2013 (the ?Effective Date?), by and between Auxilium Pharmaceuticals, Inc. (the ?Company?) and Jennifer Armstrong (?Executive?). WHEREAS, the Company and Executive entered into an employment agreement dated October |
|
| February 28, 2014 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Andrew I. Koven) Exhibit 10.51 AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Andrew I. Koven) THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into this 19th day of December, 2013 (the ?Effective Date?), by and between Auxilium Pharmaceuticals, Inc. (the ?Company?) and Andrew I. Koven (?Executive?). WHEREAS, the Company and Executive entered into an employment agreement dated February 3, 2 |
|
| February 28, 2014 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Mark Glickman) Exhibit 10.52 AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Mark Glickman) THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into this 19th day of December, 2013 (the ?Effective Date?), by and between Auxilium Pharmaceuticals, Inc. (the ?Company?) and Mark Glickman (?Executive?). WHEREAS, the Company and Executive entered into an employment agreement dated February 3, 2012 |
|
| February 28, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K Use these links to rapidly review the document TABLE OF CONTENTS ITEM 8. Financial Statements and Supplementary Data Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) |
|
| February 28, 2014 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Elizabeth Varki Jobes) Exhibit 10.56 AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Elizabeth Varki Jobes) THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into this 19th day of December, 2013 (the ?Effective Date?), by and between Auxilium Pharmaceuticals, Inc. (the ?Company?) and Elizabeth Varki Jobes (?Executive?). WHEREAS, the Company and Executive entered into an employment agreement dated A |
|
| February 28, 2014 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT (James P. Tursi, M.D.) Exhibit 10.57 AMENDED AND RESTATED EMPLOYMENT AGREEMENT (James P. Tursi, M.D.) THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into this 19th day of December, 2013 (the ?Effective Date?), by and between Auxilium Pharmaceuticals, Inc. (the ?Company?) and James P. Tursi, M.D. (?Executive?). WHEREAS, the Company and Executive entered into an employment agreement dated Aug |
|
| February 28, 2014 |
Exhibit 10.15 Confidential treatment requested under 17 C.F.R. ?? 200.80(b)(4) and 240.24b-2. The confidential portions of this exhibit have been omitted and are marked accordingly. The confidential portions have been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. COMMERCIAL SUPPLY AGREEMENT THIS COMMERCIAL SUPPLY AGREEMENT (this ?Agreeme |
|
| February 28, 2014 |
SUBSIDIARIES OF AUXILIUM PHARMACEUTICALS, INC. Exhibit 21 SUBSIDIARIES OF AUXILIUM PHARMACEUTICALS, INC. Subsidiary Jurisdiction of Incorporation Auxilium International Holdings, Inc. Delaware Auxilium US Holdings, LLC Delaware Actient Holdings LLC Delaware |
|
| February 28, 2014 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Alan J. Wills) Exhibit 10.58 AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Alan J. Wills) THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into this 19th day of December, 2013 (the ?Effective Date?), by and between Auxilium Pharmaceuticals, Inc. (the ?Company?) and Alan J. Wills (?Executive?). WHEREAS, the Company and Executive most recently entered into an employment agreement dated Dec |
|
| February 28, 2014 |
Exhibit 99.1 AUXILIUM PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS AND GUIDANCE FOR 2014 FY 2013 Net Revenues of $400.7 Million, a 32% Increase Over 2012 Non-GAAP Net Revenues FY 2013 Non-GAAP EPS Grew 77% to $0.62 2014 Guidance for Net Revenues of $450 - $490 Million CHESTERBROOK, Pa., February 28, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully inte |
|
| February 28, 2014 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Benjamin J. Del Tito, Jr., Ph.D.) Exhibit 10.55 AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Benjamin J. Del Tito, Jr., Ph.D.) THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into this 19th day of December, 2013 (the ?Effective Date?), by and between Auxilium Pharmaceuticals, Inc. (the ?Company?) and Benjamin J. Del Tito, Jr., Ph.D. (?Executive?). WHEREAS, the Company and Executive most recently entered |
|
| February 28, 2014 |
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (Adrian Adams) Exhibit 10.50 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (Adrian Adams) THIS AMENDMENT (this ?Amendment?) is entered into this 19th day of December, 2013 (the ?Effective Date?), by and between Auxilium Pharmaceuticals, Inc. (the ?Company?) and Adrian Adams (?Executive?). WHEREAS, the Company and Executive entered into an employment agreement dated December 7, 2011 providing for the terms upon which E |
|
| February 28, 2014 |
AUXILIUM PHARMACEUTICALS, INC. 2004 EQUITY COMPENSATION PLAN DEFERRED STOCK UNIT GRANT AGREEMENT Exhibit 10.38 AUXILIUM PHARMACEUTICALS, INC. 2004 EQUITY COMPENSATION PLAN DEFERRED STOCK UNIT GRANT AGREEMENT Auxilium Pharmaceuticals, Inc. (the ?Company?) has granted you deferred stock units under the Auxilium Pharmaceuticals, Inc. 2004 Equity Compensation Plan, as amended and restated (the ?Plan?). The terms of the grant are set forth in this Summary of Grant, the Deferred Stock Unit Grant Ag |
|
| February 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 18, 2014 Auxilium Pharmaceuticals, Inc. |
|
| February 24, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2014 Auxilium Pharmaceuticals, Inc. |
|
| February 24, 2014 |
Exhibit 99.1 AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES THE FDA ACCEPTANCE OF APPLICATION REQUESTING APPROVAL OF XIAFLEX® FOR THE CONCURRENT TREATMENT OF MULTIPLE PALPABLE CORDS PDUFA Date Scheduled for October 20, 2014 CHESTERBROOK, Pa., February 24, 2014 — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the U.S. Food and D |
|
| February 24, 2014 |
Exhibit 10.1 AUXILIUM PHARMACEUTICALS, INC. 2004 EQUITY COMPENSATION PLAN RESTRICTED STOCK UNIT GRANT AGREEMENT PERFORMANCE SHARE AWARD Auxilium Pharmaceuticals, Inc. (the “Company”) has granted you restricted stock units under the Auxilium Pharmaceuticals, Inc. 2004 Equity Compensation Plan, as amended and restated (the “Plan”). The terms of the grant are set forth in this Summary of Grant, the R |
|
| February 14, 2014 |
AUXL / Auxilium Pharmaceuticals Inc / Palo Alto Investors, LLC Passive Investment SC 13G/A 1 auxilium.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Auxilium Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05334D107 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 14, 2014 |
SC 13G/A 1 secfiling.htm DISCLOSURE DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Auxilium Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05334D107 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| February 14, 2014 |
AUXL / Auxilium Pharmaceuticals Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 14, 2014 |
SC 13G/A 1 sch13ga.htm AUXILIUM PHARMACEUTICALS, INC. NO. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* AUXILIUM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 05334D107 (CUSIP Number) December 31, 2013 (Date of Event which Requires Fi |
|
| February 11, 2014 |
AUXL / Auxilium Pharmaceuticals Inc / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G/A 1 AUXLsc13gal.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) AUXILIUM PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 05334D107 (CUSIP Number) DECEMBER 31, 2013 (Date of event which requires filing of this statement) Check the |
|
| February 11, 2014 |
AUXL / Auxilium Pharmaceuticals Inc / VANGUARD GROUP INC Passive Investment SC 13G/A 1 auxiliumpharma.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Auxilium Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 05334D107 Date of Event Which Requires Filing of this Statement: December 31, 2013 Check the appropriate box to designate the rule pur |
|
| February 10, 2014 |
AUXL / Auxilium Pharmaceuticals Inc / Invesco Ltd. - AUXILIUM PHARMACEUTICALS INC Passive Investment SC 13G 1 auxiliumpharminc12312013.htm AUXILIUM PHARMACEUTICALS INC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13D-1(b) AND AMENDMENTS FILED THERETO FILED PURSUANT TO RULE 13D-2(b) Under the Securities Exchange Act of 1934 (Amendment No. )* Auxilium Pharmaceuticals Inc. (Name of Issuer) Commo |
|
| February 10, 2014 |
JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) (l) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the attached Schedule 13G, and any and all amendments thereto, and expressly authorize Invesco Ltd. |
|
| January 27, 2014 |
8-K 1 a14-395928k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 24, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware 000-50855 23-3016883 (State or Other (Commission File |
|
| January 21, 2014 |
Exhibit 99.1 VIVUS AND AUXILIUM ANNOUNCE FDA ACCEPTANCE OF SUPPLEMENTAL FILING SEEKING AN UPDATE OF PRESCRIBING INFORMATION FOR STENDRA (AVANAFIL) MOUNTAIN VIEW, Calif. and CHESTERBROOK, Pa., January 21, 2014 — VIVUS, Inc. (NASDAQ: VVUS) and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental application that pr |
|
| January 21, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a14-395918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 21, 2014 Auxilium Pharmaceuticals, Inc. (Exact Name of Registrant Specified in Charter) Delaware 000-50855 23-3016883 (State or Other Jurisdiction of I |
